Michael James Burke MD
Leadership Positions
Leukemia & Lymphoma Program DirectorPublications (84)
Impact of Propofol Exposure on Neurocognitive Outcomes in Children With High-Risk B ALL: A Children's Oncology Group Study. (Alexander S, Kairalla JA, Gupta S, Hibbitts E, Weisman H, Anghelescu D, Winick NJ, Krull KR, Salzer WL, Burke MJ, Gore L, Devidas M, Embry L, Raetz EA, Hunger SP, Loh ML, Hardy KK) J Clin Oncol 2024 Apr 11:JCO2301989 PMID: 38603641 04/11/2024 Enhanced Risk Stratification for Children and Young Adults with B-Cell Acute Lymphoblastic Leukemia: A Children's Oncology Group Report. (DelRocco NJ, Loh ML, Borowitz MJ, Gupta S, Rabin KR, Zweidler-McKay P, Maloney KW, Mattano LA, Larsen E, Angiolillo A, Schore RJ, Burke MJ, Salzer WL, Wood BL, Carroll AJ, Heerema NA, Reshmi SC, Gastier-Foster JM, Harvey R, Chen IM, Roberts KG, Mullighan CG, Willman C, Winick N, Carroll WL, Rau RE, Teachey DT, Hunger SP, Raetz EA, Devidas M, Kairalla JA) Leukemia 2024 Apr;38(4):720-728 PMID: 38360863 PMCID: PMC10997503 SCOPUS ID: 2-s2.0-85185115314 02/16/2024 Novel therapies for pediatric acute lymphoblastic leukemia. (Graff Z, Burke MJ, Gossai N) Curr Opin Pediatr 2024 Feb 01;36(1):64-70 PMID: 37991046 SCOPUS ID: 2-s2.0-85181519345 11/22/2023 Outcomes in Children, Adolescents, and Young Adults With Down Syndrome and ALL: A Report From the Children's Oncology Group. (Rabin KR, Devidas M, Chen Z, Ji L, Kairalla J, Hitzler JK, Yang JJ, Carroll AJ, Heerema NA, Borowitz MJ, Wood BL, Roberts KG, Mullighan CG, Harvey RC, Chen IM, Willman CL, Reshmi SC, Gastier-Foster JM, Bhojwani D, Rheingold SR, Maloney KW, Mattano LA, Larsen EC, Schore RJ, Burke MJ, Salzer WL, Winick NJ, Carroll WL, Raetz EA, Loh ML, Hunger SP, Angiolillo AL) J Clin Oncol 2024 Jan 10;42(2):218-227 PMID: 37890117 PMCID: PMC10824380 SCOPUS ID: 2-s2.0-85181760556 10/27/2023 Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma. (Paolino J, Dimitrov B, Apsel Winger B, Sandoval-Perez A, Rangarajan AV, Ocasio-Martinez N, Tsai HK, Li Y, Robichaud AL, Khalid D, Hatton C, Gillani R, Polonen P, Dilig A, Gotti G, Kavanagh J, Adhav AA, Gow S, Tsai J, Li Y, Ebert BL, Van Allen EM, Bledsoe J, Kim AS, Tasian SK, Cooper SL, Cooper TM, Hijiya N, Sulis ML, Shukla NN, Magee JA, Mullighan CG, Burke MJ, Luskin MR, Mar BG, Jacobson MP, Harris MH, Stegmaier K, Place AE, Pikman Y) Clin Cancer Res 2023 Nov 14;29(22):4613-4626 PMID: 37725576 PMCID: PMC10872648 SCOPUS ID: 2-s2.0-85176974112 09/19/2023 Impaired neurocognitive functioning 3 months following diagnosis of high-risk acute lymphoblastic leukemia: A report from the Children's Oncology Group. (Hardy KK, Kairalla JA, Gioia AR, Weisman HS, Gurung M, Noll RB, Hinds PS, Hibbitts E, Salzer WL, Burke MJ, Winick NJ, Embry L) Pediatr Blood Cancer 2023 Jul;70(7):e30350 PMID: 37129114 PMCID: PMC10205681 SCOPUS ID: 2-s2.0-85157964010 05/02/2023 Patients with Down syndrome can be included in early phase clinical trials- a report from the T2016-003 Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) study. (Gossai N, Bhojwani D, Schafer ES, Chang BH, Pommert L, Verma A, Malvar J, Chi YY, Hitzler J, Burke MJ, Rabin KR) Leukemia 2023 May;37(5):1138-1140 PMID: 36813993 SCOPUS ID: 2-s2.0-85148507259 02/23/2023 1 CitationRacial and ethnic disparities in childhood and young adult acute lymphocytic leukaemia: secondary analyses of eight Children's Oncology Group cohort trials. (Gupta S, Dai Y, Chen Z, Winestone LE, Teachey DT, Bona K, Aplenc R, Rabin KR, Zweidler-McKay P, Carroll AJ, Heerema NA, Gastier-Foster J, Borowitz MJ, Wood BL, Maloney KW, Mattano LA Jr, Larsen EC, Angiolillo AL, Burke MJ, Salzer WL, Winter SS, Brown PA, Guest EM, Dunsmore KP, Kairalla JA, Winick NJ, Carroll WL, Raetz EA, Hunger SP, Loh ML, Devidas M) Lancet Haematol 2023 Feb;10(2):e129-e141 PMID: 36725118 PMCID: PMC9951049 SCOPUS ID: 2-s2.0-85147235386 02/02/2023 20 CitationsCentral nervous system status is prognostic in T-cell acute lymphoblastic leukemia: a Children's Oncology Group report. (Gossai NP, Devidas M, Chen Z, Wood BL, Zweidler-McKay PA, Rabin KR, Loh ML, Raetz EA, Winick NJ, Burke MJ, Carroll AJ, Esiashvili N, Heerema NA, Carroll WL, Hunger SP, Dunsmore KP, Winter SS, Teachey DT) Blood 2023 Apr 13;141(15):1802-1811 PMID: 36603187 PMCID: PMC10122105 SCOPUS ID: 2-s2.0-85150015921 01/06/2023 9 CitationsPhase 1b study of carfilzomib with induction chemotherapy in pediatric relapsed/refractory acute lymphoblastic leukemia. (Burke MJ, Ziegler DS, Bautista F, Attarbaschi A, Gore L, Locatelli F, M O'Brien M, Pauly M, Kormany WN, Tian S, Morris CL, Baruchel A) Pediatr Blood Cancer 2022 Dec;69(12):e29999 PMID: 36215217 SCOPUS ID: 2-s2.0-85139466183 10/11/2022 5 CitationsThe genomic landscape of pediatric acute lymphoblastic leukemia. (Brady SW, Roberts KG, Gu Z, Shi L, Pounds S, Pei D, Cheng C, Dai Y, Devidas M, Qu C, Hill AN, Payne-Turner D, Ma X, Iacobucci I, Baviskar P, Wei L, Arunachalam S, Hagiwara K, Liu Y, Flasch DA, Liu Y, Parker M, Chen X, Elsayed AH, Pathak O, Li Y, Fan Y, Michael JR, Rusch M, Wilkinson MR, Foy S, Hedges DJ, Newman S, Zhou X, Wang J, Reilly C, Sioson E, Rice SV, Pastor Loyola V, Wu G, Rampersaud E, Reshmi SC, Gastier-Foster J, Guidry Auvil JM, Gesuwan P, Smith MA, Winick N, Carroll AJ, Heerema NA, Harvey RC, Willman CL, Larsen E, Raetz EA, Borowitz MJ, Wood BL, Carroll WL, Zweidler-McKay PA, Rabin KR, Mattano LA, Maloney KW, Winter SS, Burke MJ, Salzer W, Dunsmore KP, Angiolillo AL, Crews KR, Downing JR, Jeha S, Pui CH, Evans WE, Yang JJ, Relling MV, Gerhard DS, Loh ML, Hunger SP, Zhang J, Mullighan CG) Nat Genet 2022 Sep;54(9):1376-1389 PMID: 36050548 PMCID: PMC9700506 SCOPUS ID: 2-s2.0-85137048816 09/02/2022 96 CitationsReal-world experience in treating pediatric relapsed/refractory or therapy-related myeloid malignancies with decitabine, vorinostat, and FLAG therapy based on a phase 1 study run by the TACL consortium. (Schafer ES, Chao K, Stevens AM, Jo E, Hilsenbeck SG, Gossai NP, Doan A, Colace SI, Guinipero T, Otterson D, Kaplan JA, Hinson A, Pommert L, Wayne AS, Bhojwani D, Burke MJ) Pediatr Blood Cancer 2022 Oct;69(10):e29812 PMID: 35726868 SCOPUS ID: 2-s2.0-85132180346 06/22/2022 5 CitationsDecitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: Report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium. (Pommert L, Schafer ES, Malvar J, Gossai N, Florendo E, Pulakanti K, Heimbruch K, Stelloh C, Chi YY, Sposto R, Rao S, Huynh VT, Brown P, Chang BH, Colace SI, Hermiston ML, Heym K, Hutchinson RJ, Kaplan JA, Mody R, O'Brien TA, Place AE, Shaw PH, Ziegler DS, Wayne A, Bhojwani D, Burke MJ) Am J Hematol 2022 May;97(5):613-622 PMID: 35180323 PMCID: PMC8986610 SCOPUS ID: 2-s2.0-85125935481 02/19/2022 23 CitationsHypersensitivity reactions to asparaginase therapy in acute lymphoblastic leukemia: immunology and clinical consequences. (Burke MJ, Zalewska-Szewczyk B) Future Oncol 2022 Mar;18(10):1285-1299 PMID: 35107320 SCOPUS ID: 2-s2.0-85126490475 02/03/2022 13 CitationsOutcomes in adolescent and young adult patients (16 to 30 years) compared to younger patients treated for high-risk B-lymphoblastic leukemia: report from Children's Oncology Group Study AALL0232. (Burke MJ, Devidas M, Chen Z, Salzer WL, Raetz EA, Rabin KR, Heerema NA, Carroll AJ, Gastier-Foster JM, Borowitz MJ, Wood BL, Winick NJ, Carroll WL, Hunger SP, Loh ML, Larsen EC) Leukemia 2022 Mar;36(3):648-655 PMID: 34725453 PMCID: PMC9014378 SCOPUS ID: 2-s2.0-85118375664 11/03/2021 12 CitationsLevocarnitine for pegaspargase-induced hepatotoxicity in older children and young adults with acute lymphoblastic leukemia. (Schulte R, Hinson A, Huynh V, Breese EH, Pierro J, Rotz S, Mixon BA, McNeer JL, Burke MJ, Orgel E) Cancer Med 2021 Nov;10(21):7551-7560 PMID: 34528411 PMCID: PMC8559504 SCOPUS ID: 2-s2.0-85114952403 09/17/2021 12 CitationsMatched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium. (Pikman Y, Tasian SK, Sulis ML, Stevenson K, Blonquist TM, Apsel Winger B, Cooper TM, Pauly M, Maloney KW, Burke MJ, Brown PA, Gossai N, McNeer JL, Shukla NN, Cole PD, Kahn JM, Chen J, Barth MJ, Magee JA, Gennarini L, Adhav AA, Clinton CM, Ocasio-Martinez N, Gotti G, Li Y, Lin S, Imamovic A, Tognon CE, Patel T, Faust HL, Contreras CF, Cremer A, Cortopassi WA, Garrido Ruiz D, Jacobson MP, Dharia NV, Su A, Robichaud AL, Saur Conway A, Tarlock K, Stieglitz E, Place AE, Puissant A, Hunger SP, Kim AS, Lindeman NI, Gore L, Janeway KA, Silverman LB, Tyner JW, Harris MH, Loh ML, Stegmaier K) Cancer Discov 2021 Jun;11(6):1424-1439 PMID: 33563661 PMCID: PMC8178162 SCOPUS ID: 2-s2.0-85107440371 02/11/2021 20 CitationsPrognostic impact of minimal residual disease at the end of consolidation in NCI standard-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group. (Rau RE, Dai Y, Devidas M, Rabin KR, Zweidler-McKay P, Angiolillo A, Schore RJ, Burke MJ, Salzer WL, Heerema NA, Carroll AJ, Winick NJ, Hunger SP, Raetz EA, Loh ML, Wood BL, Borowitz MJ) Pediatr Blood Cancer 2021 Apr;68(4):e28929 PMID: 33559396 PMCID: PMC8808711 SCOPUS ID: 2-s2.0-85100726475 02/10/2021 8 CitationsNovel germline TRAF3IP3 mutation in a dyad with familial acute B lymphoblastic leukemia. (Pommert L, Burns R, Furumo Q, Pulakanti K, Brandt J, Burke MJ, Rao S) Cancer Rep (Hoboken) 2021 Jun;4(3):e1335 PMID: 33503336 PMCID: PMC8222551 SCOPUS ID: 2-s2.0-85099938449 01/28/2021 1 CitationImpact of Intrathecal Triple Therapy Versus Intrathecal Methotrexate on Disease-Free Survival for High-Risk B-Lymphoblastic Leukemia: Children's Oncology Group Study AALL1131. (Salzer WL, Burke MJ, Devidas M, Dai Y, Hardy KK, Kairalla JA, Gore L, Hilden JM, Larsen E, Rabin KR, Zweidler-McKay PA, Borowitz MJ, Wood B, Heerema NA, Carroll AJ, Winick N, Carroll WL, Raetz EA, Loh ML, Hunger SP) J Clin Oncol 2020 Aug 10;38(23):2628-2638 PMID: 32496902 PMCID: PMC7402996 SCOPUS ID: 2-s2.0-85089203581 06/05/2020 42 CitationsConcurrent Imatinib Dosing With High-dose Methotrexate Leads to Acute Kidney Injury and Delayed Methotrexate Clearance in Pediatric Patients With Philadelphia Chromosome-positive B-Cell Acute Lymphoblastic Leukemia. (Pommert L, Liberio N, Ng JS, Egelund TA, Siver MJ, Katzenstein HM, Burke MJ) J Pediatr Hematol Oncol 2021 Mar 01;43(2):e296-e300 PMID: 32398599 SCOPUS ID: 2-s2.0-85085508892 05/14/2020 9 CitationsIsobaric Labeling Strategy Utilizing 4-Plex N,N-Dimethyl Leucine (DiLeu) Tags Reveals Proteomic Changes Induced by Chemotherapy in Cerebrospinal Fluid of Children with B-Cell Acute Lymphoblastic Leukemia. (Yu Q, Zhong X, Chen B, Feng Y, Ma M, Diamond CA, Voeller JS, Kim M, DeSantes KB, Capitini CM, Patel NJ, Hoover-Regan ML, Burke MJ, Janko K, Puccetti DM, Ikonomidou C, Li L) J Proteome Res 2020 Jul 02;19(7):2606-2616 PMID: 32396724 PMCID: PMC7334086 SCOPUS ID: 2-s2.0-85087529506 05/13/2020 9 CitationsExperience with ponatinib in paediatric patients with leukaemia. (Rossoff J, Huynh V, Rau RE, Macy ME, Sulis ML, Schultz KR, Burke MJ, Athale U, O'Brien MM, Gregory JJ Jr, van der Sluis IM, Keller FG, Zwaan CM, Suttorp M, Hijiya N) Br J Haematol 2020 Apr;189(2):363-368 PMID: 31975387 SCOPUS ID: 2-s2.0-85078788320 01/25/2020 22 CitationsDecitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: A TACL Pilot Study. (Burke MJ, Kostadinov R, Sposto R, Gore L, Kelley SM, Rabik C, Trepel JB, Lee MJ, Yuno A, Lee S, Bhojwani D, Jeha S, Chang BH, Sulis ML, Hermiston ML, Gaynon P, Huynh V, Verma A, Gardner R, Heym KM, Dennis RM, Ziegler DS, Laetsch TW, Oesterheld JE, Dubois SG, Pollard JA, Glade-Bender J, Cooper TM, Kaplan JA, Farooqi MS, Yoo B, Guest E, Wayne AS, Brown PA) Clin Cancer Res 2020 May 15;26(10):2297-2307 PMID: 31969338 PMCID: PMC7477726 SCOPUS ID: 2-s2.0-85084921034 01/24/2020 29 CitationsDesensitization to pegaspargase in children with acute lymphoblastic leukemia and lymphoblastic lymphoma. (August KJ, Farooki S, Fulbright JM, August A, Portnoy JM, Pommert L, Burke MJ, Guest EM) Pediatr Blood Cancer 2020 Jan;67(1):e28021 PMID: 31571395 SCOPUS ID: 2-s2.0-85073970426 10/02/2019 17 CitationsManagement of chronic myeloid leukemia in children and adolescents: Recommendations from the Children's Oncology Group CML Working Group. (Athale U, Hijiya N, Patterson BC, Bergsagel J, Andolina JR, Bittencourt H, Schultz KR, Burke MJ, Redell MS, Kolb EA, Johnston DL) Pediatr Blood Cancer 2019 Sep;66(9):e27827 PMID: 31330093 PMCID: PMC6944522 SCOPUS ID: 2-s2.0-85067390025 07/23/2019 51 CitationsReducing minimal residual disease with blinatumomab prior to HCT for pediatric patients with acute lymphoblastic leukemia. (Keating AK, Gossai N, Phillips CL, Maloney K, Campbell K, Doan A, Bhojwani D, Burke MJ, Verneris MR) Blood Adv 2019 Jul 09;3(13):1926-1929 PMID: 31243002 PMCID: PMC6616259 SCOPUS ID: 2-s2.0-85068800678 06/28/2019 48 CitationsWhat is the Role of Hematopoietic Cell Transplantation (HCT) for Pediatric Acute Lymphoblastic Leukemia (ALL) in the Age of Chimeric Antigen Receptor T-Cell (CART) Therapy? (Taraseviciute A, Broglie L, Phelan R, Bhatt NS, Becktell K, Burke MJ) J Pediatr Hematol Oncol 2019 Jul;41(5):337-344 PMID: 30973486 SCOPUS ID: 2-s2.0-85064242570 04/12/2019 16 CitationsCheckpoint inhibition of PD-L1 and CTLA-4 in a child with refractory acute leukemia. (Broglie L, Gershan J, Burke MJ) Int J Hematol Oncol 2019 Feb;8(1):IJH10 PMID: 30863527 PMCID: PMC6410023 03/14/2019 Allogeneic Hematopoietic Cell Transplantation Provides No Benefit for Patients With Hypodiploid Acute Lymphoblastic Leukemia. (Burke MJ) J Clin Oncol 2019 Apr 01;37(10):763-764 PMID: 30794478 SCOPUS ID: 2-s2.0-85063972440 02/23/2019 3 CitationsReplacing cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide/etoposide during consolidation/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COG. (Burke MJ, Salzer WL, Devidas M, Dai Y, Gore L, Hilden JM, Larsen E, Rabin KR, Zweidler-McKay PA, Borowitz MJ, Wood B, Heerema NA, Carroll AJ, Winick N, Carroll WL, Raetz EA, Loh ML, Hunger SP) Haematologica 2019 May;104(5):986-992 PMID: 30545921 PMCID: PMC6518909 SCOPUS ID: 2-s2.0-85065494690 12/14/2018 24 CitationsPractice Patterns of Physician Treatment for Pediatric Chronic Myelogenous Leukemia. (Andolina JR, Burke MJ, Hijiya N, Chaudhury S, Schultz KR, Roth ME) Biol Blood Marrow Transplant 2019 Feb;25(2):321-327 PMID: 30267760 SCOPUS ID: 2-s2.0-85056727740 09/30/2018 8 CitationsEpigenetic Therapy in a Patient With Down Syndrome and Refractory Acute Myeloid Leukemia. (Becktell K, Houser K, Burke MJ) J Pediatr Hematol Oncol 2019 Jan;41(1):e38-e40 PMID: 29668549 SCOPUS ID: 2-s2.0-85046027326 04/19/2018 12 CitationsLevocarnitine for asparaginase-induced hepatic injury: a multi-institutional case series and review of the literature. (Schulte RR, Madiwale MV, Flower A, Hochberg J, Burke MJ, McNeer JL, DuVall A, Bleyer A) Leuk Lymphoma 2018 Oct;59(10):2360-2368 PMID: 29431566 PMCID: PMC10183102 SCOPUS ID: 2-s2.0-85041894381 02/13/2018 13 CitationsToxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group study AALL1131. (Salzer WL, Burke MJ, Devidas M, Chen S, Gore L, Larsen EC, Borowitz M, Wood B, Heerema NA, Carroll AJ, Hilden JM, Loh ML, Raetz EA, Winick NJ, Carroll WL, Hunger SP) Cancer 2018 Mar 15;124(6):1150-1159 PMID: 29266189 PMCID: PMC5839964 SCOPUS ID: 2-s2.0-85038428590 12/22/2017 40 CitationsInvestigating the biology of relapsed acute leukemia: Proceedings of the Therapeutic Advances for Childhood Leukemia & Lymphoma (TACL) Consortium Biology Working Group. (Bhojwani D, Burke MJ, Horton T, Ziegler DS, Sulis ML, Schultz KR, Wayne A, Izraeli S, Chang BH) Pediatr Hematol Oncol 2017;34(6-7):355-364 PMID: 29190164 PMCID: PMC6191173 SCOPUS ID: 2-s2.0-85035755135 12/01/2017 1 CitationSevere pegaspargase hypersensitivity reaction rates (grade ≥3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children's oncology group (COG) clinical trials. (Burke MJ, Devidas M, Maloney K, Angiolillo A, Schore R, Dunsmore K, Larsen E, Mattano LA Jr, Salzer W, Winter SS, Carroll W, Winick NJ, Loh ML, Raetz E, Hunger SP, Bleyer A) Leuk Lymphoma 2018 Jul;59(7):1624-1633 PMID: 29115886 PMCID: PMC5940583 SCOPUS ID: 2-s2.0-85033406042 11/09/2017 34 CitationsCohesin Mutations in Myeloid Malignancies. (Fisher JB, McNulty M, Burke MJ, Crispino JD, Rao S) Trends Cancer 2017 Apr;3(4):282-293 PMID: 28626802 PMCID: PMC5472227 SCOPUS ID: 2-s2.0-85016763591 06/20/2017 31 CitationsAdministration of Dexrazoxane Improves Cardiac Indices in Children and Young Adults With Acute Myeloid Leukemia (AML) While Maintaining Survival Outcomes. (Schloemer NJ, Brickler M, Hoffmann R, Pan A, Simpson P, McFadden V, Block J, Tower RL 2nd, Burke MJ) J Pediatr Hematol Oncol 2017 Jul;39(5):e254-e258 PMID: 28452856 PMCID: PMC5591641 SCOPUS ID: 2-s2.0-85021364265 04/30/2017 14 CitationsTargetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group. (Reshmi SC, Harvey RC, Roberts KG, Stonerock E, Smith A, Jenkins H, Chen IM, Valentine M, Liu Y, Li Y, Shao Y, Easton J, Payne-Turner D, Gu Z, Tran TH, Nguyen JV, Devidas M, Dai Y, Heerema NA, Carroll AJ 3rd, Raetz EA, Borowitz MJ, Wood BL, Angiolillo AL, Burke MJ, Salzer WL, Zweidler-McKay PA, Rabin KR, Carroll WL, Zhang J, Loh ML, Mullighan CG, Willman CL, Gastier-Foster JM, Hunger SP) Blood 2017 Jun 22;129(25):3352-3361 PMID: 28408464 PMCID: PMC5482101 SCOPUS ID: 2-s2.0-85021677684 04/15/2017 210 CitationsGenomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. (Gu Z, Churchman M, Roberts K, Li Y, Liu Y, Harvey RC, McCastlain K, Reshmi SC, Payne-Turner D, Iacobucci I, Shao Y, Chen IM, Valentine M, Pei D, Mungall KL, Mungall AJ, Ma Y, Moore R, Marra M, Stonerock E, Gastier-Foster JM, Devidas M, Dai Y, Wood B, Borowitz M, Larsen EE, Maloney K, Mattano LA Jr, Angiolillo A, Salzer WL, Burke MJ, Gianni F, Spinelli O, Radich JP, Minden MD, Moorman AV, Patel B, Fielding AK, Rowe JM, Luger SM, Bhatia R, Aldoss I, Forman SJ, Kohlschmidt J, Mrózek K, Marcucci G, Bloomfield CD, Stock W, Kornblau S, Kantarjian HM, Konopleva M, Paietta E, Willman CL, Loh ML, Hunger SP, Mullighan CG) Nat Commun 2016 Nov 08;7:13331 PMID: 27824051 PMCID: PMC5105166 SCOPUS ID: 2-s2.0-84994404372 11/09/2016 207 CitationsIdentification of High-risk Cryptic CRLF2 Rearrangements in B-Cell Acute Lymphoblastic Leukemia Utilizing an FGFR3/IGH Dual-Color Dual-Fusion DNA Probe Set. (Robin AJ, Peterson JF, Grignon JW Jr, Gheorghe G, Burke MJ, vanTuinen P) J Pediatr Hematol Oncol 2017 May;39(4):e207-e210 PMID: 27820126 SCOPUS ID: 2-s2.0-84994577405 11/08/2016 2 CitationsOncolytic Seneca Valley Virus: past perspectives and future directions. (Burke MJ) Oncolytic Virother 2016;5:81-9 PMID: 27660749 PMCID: PMC5019429 09/24/2016 Differentiating hypersensitivity versus infusion-related reactions in pediatric patients receiving intravenous asparaginase therapy for acute lymphoblastic leukemia. (Burke MJ, Rheingold SR) Leuk Lymphoma 2017 Mar;58(3):540-551 PMID: 27546298 SCOPUS ID: 2-s2.0-84983048220 08/23/2016 34 CitationsTreatment-related adverse events associated with a modified UK ALLR3 induction chemotherapy backbone for childhood relapsed/refractory acute lymphoblastic leukemia. (Sun W, Orgel E, Malvar J, Sposto R, Wilkes JJ, Gardner R, Tolbert VP, Smith A, Hur M, Hoffman J, Rheingold SR, Burke MJ, Wayne AS) Pediatr Blood Cancer 2016 Nov;63(11):1943-8 PMID: 27437864 PMCID: PMC7451261 SCOPUS ID: 2-s2.0-84988358055 07/21/2016 16 CitationsA Pilot Study of Intensified PEG-Asparaginase in High-risk Acute Lymphoblastic Leukemia: Children's Oncology Group Study AALL08P1. (Rodriguez V, Kairalla J, Salzer WL, Raetz EA, Loh ML, Carroll AJ, Heerema NA, Wood BL, Borowitz MJ, Burke MJ, Asselin BL, Devidas M, Winick NJ, Carroll WL, Hunger SP, Dreyer ZE) J Pediatr Hematol Oncol 2016 Aug;38(6):409-17 PMID: 27299599 PMCID: PMC4955695 SCOPUS ID: 2-s2.0-84974724296 06/15/2016 10 CitationsMinimal Residual Disease in NPM1-Mutated AML. (Burke MJ) N Engl J Med 2016 Feb 04;374(5):481-2 PMID: 26789634 SCOPUS ID: 2-s2.0-84956923873 01/21/2016 2 CitationsDecitabine enhances chemosensitivity of early T-cell precursor-acute lymphoblastic leukemia cell lines and patient-derived samples. (Lu BY, Thanawala SU, Zochowski KC, Burke MJ, Carroll WL, Bhatla T) Leuk Lymphoma 2016 Aug;57(8):1938-41 PMID: 26726842 SCOPUS ID: 2-s2.0-84953223472 01/05/2016 23 CitationsEmerging immunotherapy in pediatric lymphoma. (Erker C, Harker-Murray P, Burke MJ) Future Oncol 2016 Jan;12(2):257-70 PMID: 26616565 SCOPUS ID: 2-s2.0-84962769178 12/01/2015 4 CitationsTransplant Outcomes for Children with T Cell Acute Lymphoblastic Leukemia in Second Remission: A Report from the Center for International Blood and Marrow Transplant Research. (Burke MJ, Verneris MR, Le Rademacher J, He W, Abdel-Azim H, Abraham AA, Auletta JJ, Ayas M, Brown VI, Cairo MS, Chan KW, Diaz Perez MA, Dvorak CC, Egeler RM, Eldjerou L, Frangoul H, Guilcher GMT, Hayashi RJ, Ibrahim A, Kasow KA, Leung WH, Olsson RF, Pulsipher MA, Shah N, Shah NN, Thiel E, Talano JA, Kitko CL) Biol Blood Marrow Transplant 2015 Dec;21(12):2154-2159 PMID: 26327632 PMCID: PMC4654112 SCOPUS ID: 2-s2.0-84947443750 09/04/2015 22 CitationsPhase I trial of Seneca Valley Virus (NTX-010) in children with relapsed/refractory solid tumors: a report of the Children's Oncology Group. (Burke MJ, Ahern C, Weigel BJ, Poirier JT, Rudin CM, Chen Y, Cripe TP, Bernhardt MB, Blaney SM) Pediatr Blood Cancer 2015 May;62(5):743-50 PMID: 25307519 PMCID: PMC4376652 SCOPUS ID: 2-s2.0-84925352074 10/14/2014 59 CitationsHow to manage asparaginase hypersensitivity in acute lymphoblastic leukemia. (Burke MJ) Future Oncol 2014 Dec;10(16):2615-27 PMID: 24983955 SCOPUS ID: 2-s2.0-84919791996 07/02/2014 42 CitationsA therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia. (Burke MJ, Lamba JK, Pounds S, Cao X, Ghodke-Puranik Y, Lindgren BR, Weigel BJ, Verneris MR, Miller JS) Am J Hematol 2014 Sep;89(9):889-95 PMID: 24891274 PMCID: PMC4134715 SCOPUS ID: 2-s2.0-84906100499 06/04/2014 83 CitationsEpigenetic modifications in pediatric acute lymphoblastic leukemia. (Burke MJ, Bhatla T) Front Pediatr 2014;2:42 PMID: 24860797 PMCID: PMC4030177 SCOPUS ID: 2-s2.0-84915754263 05/27/2014 39 CitationsA clofarabine-based bridging regimen in patients with relapsed ALL and persistent minimal residual disease (MRD). (Gossai N, Verneris MR, Karras NA, Gorman MF, Patel NJ, Burke MJ) Bone Marrow Transplant 2014 Mar;49(3):440-2 PMID: 24317126 SCOPUS ID: 2-s2.0-84904242907 12/10/2013 8 CitationsSimilar outcomes between adolescent/young adults and children with AML following allogeneic hematopoietic cell transplantation. (Burke MJ, Gossai N, Cao Q, Macmillan ML, Warlick E, Verneris MR) Bone Marrow Transplant 2014 Feb;49(2):174-8 PMID: 24185590 SCOPUS ID: 2-s2.0-84893790381 11/05/2013 19 CitationsSuspected piperacillin-tazobactam induced nephrotoxicity in the pediatric oncology population. (Pratt JA, Stricherz MK, Verghese PS, Burke MJ) Pediatr Blood Cancer 2014 Feb;61(2):366-8 PMID: 24038944 SCOPUS ID: 2-s2.0-84890874064 09/17/2013 31 CitationsHow do we define complete remission for acute myeloid leukemia in the current era? Results of an international survey. (Burke MJ, Burns L, Linden MA, Lindgren B, Verneris MR, Weisdorf D, Ustun C) Am J Hematol 2013 Sep;88(9):826-7 PMID: 23737091 PMCID: PMC3772519 SCOPUS ID: 2-s2.0-84882714075 06/06/2013 2 CitationsAllogeneic hematopoietic cell transplantation in first remission abrogates poor outcomes associated with high-risk pediatric acute myeloid leukemia. (Burke MJ, Wagner JE, Cao Q, Ustun C, Verneris MR) Biol Blood Marrow Transplant 2013 Jul;19(7):1021-5 PMID: 23567175 PMCID: PMC3712759 SCOPUS ID: 2-s2.0-84879339630 04/10/2013 23 CitationsEarly hematopoietic stem cell transplant is associated with favorable outcomes in children with MDS. (Smith AR, Christiansen EC, Wagner JE, Cao Q, MacMillan ML, Stefanski HE, Trotz BA, Burke MJ, Verneris MR) Pediatr Blood Cancer 2013 Apr;60(4):705-10 PMID: 23152304 PMCID: PMC3668778 SCOPUS ID: 2-s2.0-84873720700 11/16/2012 22 CitationsA phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report. (Widemann BC, Kim A, Fox E, Baruchel S, Adamson PC, Ingle AM, Glade Bender J, Burke M, Weigel B, Stempak D, Balis FM, Blaney SM) Clin Cancer Res 2012 Nov 01;18(21):6011-22 PMID: 22962440 PMCID: PMC4008314 SCOPUS ID: 2-s2.0-84868543745 09/11/2012 100 CitationsSurvival differences between adolescents/young adults and children with B precursor acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation. (Burke MJ, Gossai N, Wagner JE, Smith AR, Bachanova V, Cao Q, MacMillan ML, Stefanski HS, Weisdorf DJ, Verneris MR) Biol Blood Marrow Transplant 2013 Jan;19(1):138-42 PMID: 22960388 PMCID: PMC3530019 SCOPUS ID: 2-s2.0-84871918387 09/11/2012 29 CitationsEpigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia. (Bhatla T, Wang J, Morrison DJ, Raetz EA, Burke MJ, Brown P, Carroll WL) Blood 2012 May 31;119(22):5201-10 PMID: 22496163 PMCID: PMC3369610 SCOPUS ID: 2-s2.0-84861904198 04/13/2012 117 CitationsUnrelated cord blood transplantation in adult and pediatric acute lymphoblastic leukemia: effect of minimal residual disease on relapse and survival. (Bachanova V, Burke MJ, Yohe S, Cao Q, Sandhu K, Singleton TP, Brunstein CG, Wagner JE, Verneris MR, Weisdorf DJ) Biol Blood Marrow Transplant 2012 Jun;18(6):963-8 PMID: 22430088 PMCID: PMC3631589 SCOPUS ID: 2-s2.0-84860796306 03/21/2012 38 CitationsAllogeneic hematopoietic cell transplantation (allo-HCT) outcomes for children with B-precursor ALL and early or late BM relapse (Burke MJ, Verneris MR, Beck JC) Bone Marrow Transplantation December 2011;46(12):1571-1572 SCOPUS ID: 2-s2.0-84856115719 12/01/2011 Impact of bone marrow hematogones on umbilical cord blood transplantation outcomes in patients with acute myeloid leukemia. (Honebrink T, Dayton V, Burke MJ, Larsen K, Cao Q, Brunstein C, Weisdorf D, Miller JS, Wagner JE, Verneris MR) Biol Blood Marrow Transplant 2012 Jun;18(6):930-6 PMID: 22108570 PMCID: PMC4378716 SCOPUS ID: 2-s2.0-84860835017 11/24/2011 23 CitationsTreatment of relapsed acute lymphoblastic leukemia: approaches used by pediatric oncologists and bone marrow transplant physicians. (Burke MJ, Lindgen B, Verneris MR) Pediatr Blood Cancer 2012 Jun;58(6):840-5 PMID: 21796765 SCOPUS ID: 2-s2.0-84858685922 07/29/2011 4 CitationsAllogeneic hematopoietic stem cell transplantation overcomes the adverse prognostic impact of CD20 expression in acute lymphoblastic leukemia. (Bachanova V, Sandhu K, Yohe S, Cao Q, Burke MJ, Verneris MR, Weisdorf D) Blood 2011 May 12;117(19):5261-3 PMID: 21403127 PMCID: PMC3109547 SCOPUS ID: 2-s2.0-79955976375 03/16/2011 12 CitationsAllogeneic hematopoietic cell transplantation outcomes for children with B-precursor acute lymphoblastic leukemia and early or late BM relapse. (Beck JC, Cao Q, Trotz B, Smith AR, Weigel BJ, Verneris MR, Burke MJ) Bone Marrow Transplant 2011 Jul;46(7):950-5 PMID: 20856210 SCOPUS ID: 2-s2.0-79960167283 09/22/2010 15 CitationsEarly lymphocyte recovery and outcomes after umbilical cord blood transplantation (UCBT) for hematologic malignancies. (Burke MJ, Vogel RI, Janardan SK, Brunstein C, Smith AR, Miller JS, Weisdorf D, Wagner JE, Verneris MR) Biol Blood Marrow Transplant 2011 Jun;17(6):831-40 PMID: 20831896 PMCID: PMC3412271 SCOPUS ID: 2-s2.0-79956010659 09/14/2010 29 CitationsOutcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors. (Shaw PJ, Kan F, Woo Ahn K, Spellman SR, Aljurf M, Ayas M, Burke M, Cairo MS, Chen AR, Davies SM, Frangoul H, Gajewski J, Gale RP, Godder K, Hale GA, Heemskerk MB, Horan J, Kamani N, Kasow KA, Chan KW, Lee SJ, Leung WH, Lewis VA, Miklos D, Oudshoorn M, Petersdorf EW, Ringdén O, Sanders J, Schultz KR, Seber A, Setterholm M, Wall DA, Yu L, Pulsipher MA) Blood 2010 Nov 11;116(19):4007-15 PMID: 20671124 PMCID: PMC2981549 SCOPUS ID: 2-s2.0-78149432602 07/31/2010 98 CitationsLower leukemia relapse in pediatric patients with pulmonary cytolytic thrombi following allogeneic transplant. (Smith AR, Gulbahce E, Burke MJ, Cao Q, Macmillan ML, Tolar J, Orchard PJ, Blazar BR, Baker KS, Wagner JE, Verneris MR) Bone Marrow Transplant 2011 Mar;46(3):368-71 PMID: 20548337 PMCID: PMC3556271 SCOPUS ID: 2-s2.0-79952535218 06/16/2010 6 CitationsNovel approaches to prevent leukemia relapse following allogeneic hematopoietic cell transplantation. (Verneris MR, Burke MJ) Curr Hematol Malig Rep 2010 Jul;5(3):157-62 PMID: 20446122 SCOPUS ID: 2-s2.0-77955980418 05/07/2010 3 CitationsReduced-intensity conditioning regimens for allogeneic transplantation in children with acute lymphoblastic leukemia. (Verneris MR, Eapen M, Duerst R, Carpenter PA, Burke MJ, Afanasyev BV, Cowan MJ, He W, Krance R, Li CK, Tan PL, Wagner JE, Davies SM) Biol Blood Marrow Transplant 2010 Sep;16(9):1237-44 PMID: 20302960 PMCID: PMC2904410 SCOPUS ID: 2-s2.0-77955512467 03/23/2010 35 CitationsResponse of refractory immune thrombocytopenia after bone marrow transplantation to romiplostim. (Beck JC, Burke MJ, Tolar J) Pediatr Blood Cancer 2010 Mar;54(3):490-1 PMID: 19908296 SCOPUS ID: 2-s2.0-76749161291 11/13/2009 24 CitationsAllogeneic hematopoietic cell transplantation (allogeneic HCT) for treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). (Burke MJ, Cao Q, Trotz B, Weigel B, Kumar A, Smith A, Verneris MR) Pediatr Blood Cancer 2009 Dec 15;53(7):1289-94 PMID: 19731318 SCOPUS ID: 2-s2.0-70449711283 09/05/2009 24 CitationsRelapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units. (Verneris MR, Brunstein CG, Barker J, MacMillan ML, DeFor T, McKenna DH, Burke MJ, Blazar BR, Miller JS, McGlave PB, Weisdorf DJ, Wagner JE) Blood 2009 Nov 05;114(19):4293-9 PMID: 19706886 PMCID: PMC2774557 SCOPUS ID: 2-s2.0-77950404594 08/27/2009 237 CitationsThe treatment of pediatric Philadelphia positive (Ph+) leukemias in the imatinib era. (Burke MJ, Willert J, Desai S, Kadota R) Pediatr Blood Cancer 2009 Dec;53(6):992-5 PMID: 19621426 SCOPUS ID: 2-s2.0-71049160882 07/22/2009 9 CitationsImatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients. (Burke MJ, Trotz B, Luo X, Weisdorf DJ, Baker KS, Wagner JE, Verneris MR) Bone Marrow Transplant 2009 Aug;44(3):169-74 PMID: 19204709 SCOPUS ID: 2-s2.0-68949088557 02/11/2009 11 CitationsTreatment of a CNS relapse while on therapy for Burkitt lymphoma. (Burke MJ, Dayton V) Pediatr Blood Cancer 2009 Feb;52(2):290-2 PMID: 18937319 SCOPUS ID: 2-s2.0-59449110216 10/22/2008 2 CitationsAllo-hematopoietic cell transplantation for Ph chromosome-positive ALL: impact of imatinib on relapse and survival. (Burke MJ, Trotz B, Luo X, Baker KS, Weisdorf DJ, Wagner JE, Verneris MR) Bone Marrow Transplant 2009 Jan;43(2):107-13 PMID: 18776928 SCOPUS ID: 2-s2.0-59549085066 09/09/2008 47 CitationsCardiac risks of imatinib in chronic myelogenous leukemia (CML) patients who receive allogeneic hematopoietic cell transplantation (Allo-HCT). (Burke MJ, Gursahaney A, Trotz B, Luo X, Baker KS, Weisdorf DJ, Wagner JE, Michael VR) J Clin Oncol 2008 May 20;26(15_suppl):7039 PMID: 27949600 05/20/2008 Tandem high-dose chemotherapy with autologous peripheral hematopoietic progenitor cell rescue as consolidation therapy for patients with high-risk Ewing family tumors. (Burke MJ, Walterhouse DO, Jacobsohn DA, Duerst RE, Kletzel M) Pediatr Blood Cancer 2007 Aug;49(2):196-8 PMID: 17417796 SCOPUS ID: 2-s2.0-34447256148 04/10/2007 26 CitationsRituximab for treatment of opsoclonus-myoclonus syndrome in neuroblastoma. (Burke MJ, Cohn SL) Pediatr Blood Cancer 2008 Mar;50(3):679-80 PMID: 16900484 SCOPUS ID: 2-s2.0-38549143161 08/11/2006 18 Citations
© 2024 Clinical & Translational Science Institute